|
- Venetoclax in Patients with Multiple Myeloma with or without t(11;14 . . .
Introduction: Although not formally approved for the treatment of multiple myeloma (MM), the BCL2 inhibitor venetoclax (ven) has shown promising activity in patients (pts) with MM whose disease harbors t (11;14)
- Venetoclax for the treatment of multiple myeloma: Outcomes . . . - PubMed
Multiple myeloma (MM) remains an incurable disease despite incorporation of novel agents Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy in patients with MM, particularly those harboring …
- Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World . . .
Venetoclax-based therapy in translocation t (11;14) myeloma represents a unique targeted approach, however it is not yet approved by relevant authorities In our real-world study, efficacy and safety of this approach was retrospectively studied on 58 patients who had individual off label usage approval and funding by Hungarian authorities
- Phase III CANOVA Trial of Venetoclax | Intl Myeloma Foundation
AbbVie has announced data from its Phase III CANOVA study, which evaluated the safety and efficacy of venetoclax plus dexamethasone for patients with t(11;14)-positive relapsed or refractory multiple myeloma The results did not show a significant improvement in progression-free survival compared to pomalidomide plus dexamethasone However, secondary endpoints such as overall response rate and
- Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite . . .
Despite its lack of FDA approval and initial safety concerns, venetoclax remains widely used in patients with t (11;14) myeloma due to its established mechanism and clinical efficacy in this disease subgroup
- Efficacy and safety of venetoclax-based regimens for the treatment of . . .
Conclusion: Venetoclax-based therapy is an effective and safe option for RRMM patients, especially those with t (11;14) Keywords: multiple myeloma, t (11;14), therapy, venetoclax Introduction Multiple myeloma (MM) is a plasma cell disorder characterized by the proliferation of clonal plasma cells and the secretion of monoclonal proteins
- Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or . . .
Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t (11;14) translocation Venetoclax efficacy in RRMM may be potentiated through combination with agents including bortezomib, dexamethasone, and daratumumab
- Studies Explore Efficacy of Venetoclax in t(11;14)-Positive Myeloma
In the global randomized phase III CANOVA study, venetoclax plus dexamethasone (VenDex) demonstrated numerically longer progression-free survival compared with pomalidomide and dexamethasone (PomDex) in patients with t (11;14)-positive relapsed or refractory multiple myeloma, though the difference was not statistically significant In a post hoc sensitivity analysis, however, median
|
|
|